Corvus Pharmaceuticals (Corvus Pharmaceuticals) Days Sales Outstanding

: 0.00 (As of Dec. 2023)

View and export this data going back to 2016. Start your Free Trial

Corvus Pharmaceuticals's average Accounts Receivable for the three months ended in Dec. 2023 was $0.02 Mil. Corvus Pharmaceuticals's Revenue for the three months ended in Dec. 2023 was $0.00 Mil.

The historical rank and industry rank for Corvus Pharmaceuticals's Days Sales Outstanding or its related term are showing as below:

CRVS's Days Sales Outstanding is not ranked ^*
in the Biotechnology industry.
Industry Median: 72.76
* Ranked among companies with meaningful Days Sales Outstanding only.

Corvus Pharmaceuticals's Days Sales Outstanding stayed the same from Dec. 2022 (0.00) to Dec. 2023 (0.00).

Corvus Pharmaceuticals Days Sales Outstanding Historical Data

The historical data trend for Corvus Pharmaceuticals's Days Sales Outstanding can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Corvus Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Days Sales Outstanding

Corvus Pharmaceuticals Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Days Sales Outstanding																-	-	-	-	-

Competitive Comparison

For the Biotechnology subindustry, Corvus Pharmaceuticals's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Corvus Pharmaceuticals Days Sales Outstanding Distribution

For the Biotechnology industry and Healthcare sector, Corvus Pharmaceuticals's Days Sales Outstanding distribution charts can be found below:

* The bar in red indicates where Corvus Pharmaceuticals's Days Sales Outstanding falls into.

Corvus Pharmaceuticals Days Sales Outstanding Calculation

Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Accounts Receivable can be measured by Days Sales Outstanding.

Corvus Pharmaceuticals's Days Sales Outstanding for the fiscal year that ended in Dec. 2023 is calculated as

	Days Sales Outstanding (A: Dec. 2023 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Dec. 2022 )	+	Accounts Receivable (A: Dec. 2023 ))	/	count )	/	Revenue (A: Dec. 2023 )	*	Days in Period
=	( (0.588	+	0.026)	/	2 )	/	0	*	365
=	0.307					/	0	*	365
=	N/A

Corvus Pharmaceuticals's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

	Days Sales Outstanding (Q: Dec. 2023 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Sep. 2023 )	+	Accounts Receivable (A: Dec. 2023 ))	/	count )	/	Revenue (A: Dec. 2023 )	*	Days in Period
=	( (0.011	+	0.026)	/	2 )	/	0	*	365 / 4
=	0.0185					/	0	*	365 / 4
=	N/A

Corvus Pharmaceuticals (NAS:CRVS) Days Sales Outstanding Explanation

For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.

Corvus Pharmaceuticals Days Sales Outstanding Related Terms

Thank you for viewing the detailed overview of Corvus Pharmaceuticals's Days Sales Outstanding provided by GuruFocus.com. Please click on the following links to see related term pages.

Corvus Pharmaceuticals (Corvus Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Corvus Pharmaceuticals Inc (NAS:CRVS) » Definitions » Days Sales Outstanding

Comparable Companies

Traded in Other Exchanges

C17:Germany

Address

863 Mitten Road, Suite 102, Burlingame, CA, USA, 94010

Website

https://www.corvuspharma.com

Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical engaged in developing drugs and antibodies that target the most critical cellular elements of the immune system. It focuses on the development of immune modulator product candidates to treat COVID-19, T-cell lymphomas, other cancers and autoimmune diseases. The company's lead product candidate is CPI-006 which is a potent humanized monoclonal antibody that is designed to react with a specific site on CD73. Its other product candidates are CPI-818, CPI-935, CPI-182 and Ciforadenant.

Executives

Linda S Grais	director	86 ALEJANDRA AVE, ATHERTON CA 94027
William Benton Jones	officer: See Remarks	863 MITTEN ROAD, SUITE 102, BURLINGAME CA 94010
Leiv Lea	officer: Chief Financial Officer	PHARMACYCLICS INC, 995 E ARQUES AVE, SUNNYVALE CA 94085-4521
Miller Richard A Md	director, officer: President and CEO	PHARMACYCLICS INC, 995 E ARQUES AVE, SUNNYVALE CA 94085-4521
Ecor1 Capital, Llc	10 percent owner	357 TEHAMA STREET #3, SAN FRANCISCO CA 94103
Peter A. Thompson	director, 10 percent owner	C/O ANTHERA PHARMACEUTICALS, INC., 25801 INDUSTRIAL BOULEVARD, SUITE B, HAYWARD CA 94545
Orbimed Advisors Llc	director	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Edith P. Mitchell	director	1640 MARENGO ST., LOS ANGELES CA 90033
Novo Holdings A/s	10 percent owner	TUBORG HAVNEVEJ 19, HELLERUP G7 2900
Mehrdad Mobasher	officer: Chief Medical Officer	863 MITTEN ROAD, BURLINGAME CA 94010
Adams Street Partners Llc	10 percent owner	ONE NORTH WACKER DRIVE, STE 2700, CHICAGO IL 60606-2807
Terry P Gould	director, 10 percent owner	C/O ONCOMED PHARMACEUTICALS, INC., 800 CHESAPEAKE DRIVE, REDWOOD CITY CA 94063
Joseph J Buggy	officer: EVP Discovery Research	CORVUS PHARMACEUTICALS, INC., 863 MITTEN ROAD, SUITE 102, BURLINGAME CA 94010
Daniel W. Hunt	officer: SVP, Chief Business Officer	863 MITTEN ROAD, SUITE 102, BURLINGAME CA 94010
Erik J. Verner	officer: V.P., Chemistry Research	863 MITTEN ROAD, SUITE 102, BURLINGAME CA 94010